The Clinicopathologic Characteristics and 5-year Survival Rate of Epithelial Ovarian Cancer in Yazd, Iran
Keywords:
Epithelial ovarian cancer, epidemiologic points, survival rate, tumor pathologyAbstract
Introduction: Ovarian cancer is the second most common malignancy in women, the most common cause of gynecologic cancer deaths, and most patients have advanced stage disease at the time of diagnosis. The purpose of this study was to estimate the 5-year survival of patients with epithelial ovarian cancer based on age, tumor histology, stage of disease, and type of treatment.
Methods: This study was conducted on 120 patients with epithelial ovarian cancer referred to Shahid Sadoughi hospital and Shah Vali oncology clinic of Yazd from 2006 to 2012. Demographic data and patient records were studied to evaluate the treatment outcome, pathology of the tumor, and stage of disease. Finally, the overall survival rate and tumor-free survival of patients was assessed.
Results: The mean patient age was 53.87± 14.11 years. Most participants had stage I (36.7%) or stage II (35%) disease. Serous adenocarcinoma (57.6%) was the most common pathology found in patients with epithelial ovarian cancer. The overall survival of patients in this study was significantly associated with the histological tumor type (p = 0.000) and disease stage (p = 0.0377). Stage I (84.18%) and serous adenocarcinoma (72.81%) demonstrated the best survival. The tumor-free survival rates were not associated with histology types (p = 0.079), surgical procedure (p = 0.18), or chemotherapy (p = 0.18).
Conclusion: The survival of patients with epithelial ovarian cancer was significantly associated with disease stage. Serous adenocarcinoma also had the best prognosis among the pathologies studied. Therefore, early detection of ovarian cancer can substantially increase the survival rate.
References
Siegel R, Ward E, Brawley O, Jemal A. The impact of eliminating socioeconomic and racial disparities on
premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-36, doi: 10.3322/caac.20121. PMid: 21685461
Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced
refractory epithelial ovarian cancer. Gynecol Oncol. 2005;96(3):902-5, doi: 10.1016/j.ygyno.2004.12.001.
PMid: 15721449
Berek JS, Adashi EY, Hillard PA, Novak ER. Novak's gynecology: Williams & Wilkins; 1996.
Ghaemmaghami F, Karimi-Zarchi M, Modares-Gilani M, Mousavi A, Behtash N. Clinical outcome of
Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking
surgery. Asian Pac J Cancer Prev. 2008;9(4):719-24. PMid: 19256766
Buehler M, Tse B, Leboucq A, Jacob F, Caduff R, Fink D, et al. Meta-analysis of microarray data identifies
GAS6 expression as an independent predictor of poor survival in ovarian cancer. Biomed Res Int.
;2013:238284. doi: 10.1155/2013/238284. PMID: 23878800, PMCID: PMC3710590
Sardi J, Anchezar P, Bermudez A. Favorable clinical behavior in young ovarian carcinoma patients: a
rationale for conservative surgery? Int J Gynecol Cancer. 2005;15(5):762-9, doi: 10.1111/j.1525- 1438.2005.00133.x. PMid: 16174221
Behtash N, Zarchi MK, Gilani MM, Ghaemmaghami F, Mousavi A, Ghotbizadeh F. Ovarian carcinoma
associated with pregnancy: a clinicopathologic analysis of 23 cases and review of the literature. BMC
Pregnancy Childbirth. 2008;8(1):3, doi: 10.1186/1471-2393-8-3. PMid: 18205951, PMCid: PMC2266699
Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. International Journal
of Gynecology & Obstetrics. 2009;105(2):107-8, doi: 10.1016/j.ijgo.2009.02.012.
Ghaemmaghami F, Hassanzadeh M, Karimi-Zarchi M, Modari-Gilani M, Behtash N, Mousavi A.
Centralization of ovarian cancer surgery: do patients benefit Eur J Gynaecol Oncol. 2010;31(4):429, PMid:
Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, et al. Patterns and progress in
ovarian cancer over 14 years. Obstet Gynecol. 2006;108(3, Part 1):521-8, doi:
1097/01.AOG.0000231680.58221.a7. PMid: 16946210
Diane M. Provencher, MD. Epithelial Ovarian Cancer: Not So Asymptomatic. The Canadian Journal of
Diagnosis (Women’s Health Care). April 2001: 75-85. Available from:
http://www.stacommunications.com/journals/diagnosis/images/diagnosispdf/april01/whc.pdf
Tanaka Y, Terai Y, Tanabe A, Sasaki H, Sekijima T, Fujiwara S, et al. Prognostic effect of epidermal
growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer.
Cancer Biol Ther. 2011;11(1):50-7, doi: 10.4161/cbt.11.1.13877. PMID: 21057220, PMCid: PMC3047101
Pilli GS, Suneeta K, Dhaded A, Yenni V. Ovarian tumours: a study of 282 cases. J Indian Med Assoc.
;100(7):420, 3-4, 47. PMID: 12674165
Fotopoulou C, Savvatis K, Schumacher G, Lichtenegger W, Sehouli J. Surgical outcome and survival
analysis of young patients with primary epithelial ovarian cancer. Anticancer research. 2009;29(7):2809- 15. PMid: 19596966
Karabuk E, Kose MF, Hizli D, Taşkin S, Karadağ B, Turan T, et al. Comparison of advanced stage
mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and
survival outcome: a matched case-control study. J Gynecol Oncol. 2013;24(2):160-6, doi:
3802/jgo.2013.24.2.160. PMid: 23653834, PMCid: PMC3644693
Kikkawa F, Nawa A, Ino K, Sibata K, Kajiyama H, Nomura S, et al. Advances in treatment of epithelial
ovarian cancer. Nagoya journal of medical science. 2006;68(1-2):19-26. PMid: 16579172
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz F. Survival effect of maximal
cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin
Oncol. 2002;20(5):1248-59, doi: 10.1200/JCO.20.5.1248. PMid: 11870167
Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P. Interval debulking surgery for
advanced epithelial ovarian cancer: a Cochrane systematic review. Gynecol Oncol. 2009;112(1):257-64,
doi: 10.1016/j.ygyno.2008.09.041. PMid: 19017548
Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi DA, Santin AD, et al. Neoadjuvant chemotherapy
(NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage
IIIC and IV). J Surg Oncol. 2013;107(2):195-200, doi: 10.1002/jso.23171. PMid: 22648987
Morrison J, Swanton A, Collins S, Kehoe S. Chemotherapy versus surgery for initial treatment in advanced
ovarian epithelial cancer. The Cochrane Library. 2007. PMID: 17943850
Van Altena AM, Karim-Kos HE, de Vries E, Kruitwagen RF, Massuger LF, Kiemeney LA. Trends in
therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. Gynecol
Oncol. 2012;125(3):649-54, doi: 10.1016/j.ygyno.2012.02.033. PMid: 22370602
Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al. Ten-year relative survival
for epithelial ovarian cancer. Obstet Gynecol. 2012;120(3):612-8, doi: 10.1097/AOG.0b013e318264f794.
PMid: 22914471
Bamias A, Karadimou A, Soupos N, Sotiropoulou M, Zagouri F, Haidopoulos D, et al. Prognostic factors
for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a
single institution experience. Gynecol Oncol. 2011;123(1):37-42, doi: 10.1016/j.ygyno.2011.06.033. PMid:
Kirwan JM, Tincello DG, Herod JJ, Frost O, Kingston RE. Effect of delays in primary care referral on
survival of women with epithelial ovarian cancer: retrospective audit. Bmj. 2002;324(7330):148-51, doi:
1136/bmj.324.7330.148. PMid: 11799032, PMCid: PMC64516
Grann AF, Thomsen RW, Jacobsen JB, Nørgaard M, Blaakær J, Søgaard M. Comorbidity and survival of
Danish ovarian cancer patients from 2000–2011: a population-based cohort study. Clin Epidemiol.
;5(Suppl 1):57, doi: 10.2147/CLEP.S47205. PMid: 24265559, PMCid: PMC3833012
Najafi Z, Rivaz M, Shokrollahi P, Shamsnia M. Survival rate of women with ovarian cancer in Fars
Province, Iran. Bimonthly Journal of Hormozgan University of Medical Sciences. 2013;16(6):459-65,
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
